The insulin pricing lawsuit landscape shifted dramatically in July 2026, as a federal appeals court dismissed the pharmacy benefit managers’ (PBMs’) countersuit against the Federal Trade Commission, regulatory settlements with two of the three major PBMs took shape, and a sprawling multi-district litigation continued to gather momentum in New Jersey. For the millions of Americans with diabetes who have watched insulin prices climb more than 1,000% over two decades, these converging legal and regulatory actions represent the most significant accountability push in the history of insulin pricing in the United States.
What Is the Insulin Pricing Lawsuit and Why It Matters in 2026
The insulin pricing lawsuit known formally as In re: Insulin Pricing Litigation, MDL 3080, is pending before Judge Brian R. Martinotti in the U.S. District Court for the District of New Jersey. As of January 2026, the Judicial Panel on Multidistrict Litigation reported 444 consolidated lawsuits pending in the docket. The defendants named across these cases include insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi, alongside pharmacy benefit managers CVS Caremark, Express Scripts, and OptumRx — collectively accused of orchestrating a scheme to artificially inflate insulin list prices while extracting rebates that enriched the supply chain at the expense of patients paying out of pocket.
The core allegation is straightforward but staggering in scale: insulin list prices rose more than 1,000% over the past 20 years, not because of innovation or manufacturing costs, but because of a coordinated rebate system that rewarded PBMs for placing higher-priced insulins on formularies. The FTC has found that the three PBMs named in MDL 3080 hold oligopolistic control over approximately 80% of U.S. prescriptions, giving them extraordinary leverage over which drugs patients can access and at what cost.
FTC Regulatory Actions: Settlements, Consent Orders, and a Court Victory
Express Scripts Landmark Settlement — February 2026
On February 4, 2026, the Federal Trade Commission secured what it described as a landmark settlement with Express Scripts (operating under Cigna’s Evernorth subsidiary). Under the terms of the agreement, Express Scripts must stop preferring high-list-price drugs on its standard formularies and must delink its compensation from manufacturer savings negotiations — a structural change designed to eliminate the financial incentive that critics say drove insulin prices upward for years. The FTC estimates these changes could lower patient out-of-pocket insulin costs by up to $7 billion over 10 years. For diabetic patients whose insulin costs ballooned under Express Scripts-administered plans, this settlement is both a vindication and a potential source of future savings.
CVS Caremark Proposed Consent Order — March 23, 2026
Less than seven weeks after the Express Scripts agreement, the FTC announced a proposed consent order with CVS Caremark on March 23, 2026. While the Caremark order was still in its proposed phase as of this writing, it follows the same structural logic as the Express Scripts settlement, targeting formulary design practices and compensation arrangements that allegedly kept high-list-price insulins in preferred positions. Caremark’s consent order is subject to a public comment period before it becomes final, but its announcement signals that the FTC’s pressure campaign against PBMs is producing results across the industry.
OptumRx Still in Adversarial FTC Proceedings
OptumRx, the pharmacy benefit arm of UnitedHealth Group, has not reached a settlement as of July 2026. The company remains in adversarial FTC proceedings, currently entangled in a discovery dispute that has slowed the administrative process. Unlike its two counterparts, OptumRx has not moved toward resolution, making it the last PBM still actively resisting FTC scrutiny in a formal adversarial posture.
8th Circuit Dismisses PBMs’ Countersuit — July 2026
In a significant legal development that occurred within the past two weeks, the U.S. Court of Appeals for the 8th Circuit dismissed the PBMs’ countersuit against the FTC on or about July 8, 2026. All three PBMs — Express Scripts, CVS Caremark, and OptumRx — had filed a joint stipulation to end the case, which they had originally launched in November 2024 in an attempt to block the FTC’s administrative proceedings. The 8th Circuit had already denied the PBMs’ injunction request in March 2025. The dismissal eliminates a procedural obstacle that could have delayed accountability and reinforces the FTC’s authority to pursue its administrative actions to conclusion.
MDL 3080: Who Is Suing, and What Happened in June 2026
The civil insulin pricing lawsuit in MDL 3080 has expanded significantly in 2026, with both governmental and private plaintiffs joining the consolidated docket. State attorneys general from Delaware, Missouri, Indiana, and Oregon have joined the litigation, as have major health systems in Kentucky, Missouri, Pennsylvania, and Tennessee. Hamilton County, Ohio (home to Cincinnati) joined the MDL in February 2026, and the Toro Company — a Minnesota-based manufacturer — entered the case as a self-funded payer plaintiff, illustrating how broadly the alleged pricing scheme affected employers who fund their own employee health plans. If you believe your organization or health plan suffered financial harm from inflated insulin costs, a medical malpractice calculator can help you begin estimating the scope of economic damages in a defective drug pricing context.
On June 1, 2026, Judge Martinotti granted the self-funded payer plaintiffs permission to amend their complaints in the MDL — a procedural green light that allows these plaintiffs to sharpen their allegations in light of the FTC’s regulatory findings and new evidence developed during discovery. Amended complaints are a critical milestone in mass tort litigation because they typically incorporate the most current facts and legal theories, making cases harder to dismiss at later stages.
At the state level, the Michigan Supreme Court agreed to hear Attorney General Dana Nessel’s challenge against Eli Lilly under the Michigan Consumer Protection Act, a development that could establish important state-law precedent applicable not only in Michigan but in other states with similar consumer protection statutes.
Key Statistics in the Insulin Pricing Lawsuit
| Metric | Figure | Source |
|---|---|---|
| Cases pending in MDL 3080 (as of Jan. 2026) | 444 lawsuits | JPML, January 2026 |
| Estimated patient savings from Express Scripts settlement | Up to $7 billion over 10 years | FTC, February 2026 |
| Extra revenue generated by PBMs from inflated specialty generic drug prices | $7.3 billion | FTC Report, 2026 |
| PBM control over U.S. prescriptions | ~80% oligopolistic market share | FTC Report, 2026 |
| Increase in insulin list prices over past 20 years | More than 1,000% | MDL 3080 plaintiffs’ allegations, 2026 |
| Date PBMs’ 8th Circuit countersuit dismissed | On or about July 8, 2026 | 8th Circuit, July 2026 |
| MDL amended complaint authorization date | June 1, 2026 | Judge Martinotti, D.N.J., 2026 |
What Diabetic Patients Can Do Right Now
The insulin pricing lawsuit is not solely a story about governments and corporations. Individual diabetic patients who paid inflated out-of-pocket costs for insulin — including those on high-deductible health plans, those who paid full list price during coverage gaps, and those who rationed insulin due to cost — may have legal standing to participate in or benefit from mass tort proceedings. While MDL 3080 currently focuses primarily on state AG claims and self-funded payer claims, the underlying allegations about harm to patients form the factual foundation for individual and class actions that are likely to develop as this litigation matures. Using a personal injury settlement calculator can give you a preliminary sense of what economic and non-economic damages might be worth in a consumer harm context.
Patients should begin gathering documentation now: pharmacy receipts showing insulin prices paid over time, insurance explanation-of-benefits statements, records of out-of-pocket costs, and any documentation of medical consequences from rationing or cost-driven disruptions to insulin therapy. The more detailed and organized your records, the stronger the potential evidentiary foundation for a future claim. The CDC’s diabetes data resources can help you contextualize the medical burden and understand how pricing disruptions intersect with clinical outcomes.
Timing matters in mass tort litigation. As amended complaints are filed, as the FTC consent orders are finalized, and as discovery in MDL 3080 continues to surface internal communications between manufacturers and PBMs, the evidentiary landscape will evolve rapidly. Patients and self-funded payers who wait too long risk missing applicable statutes of limitations, which vary by state and by type of claim.
Frequently Asked Questions About the Insulin Pricing Lawsuit
Who are the defendants in MDL 3080, and what did they allegedly do?
The defendants in MDL 3080 include the three largest insulin manufacturers — Eli Lilly, Novo Nordisk, and Sanofi — along with the three largest pharmacy benefit managers: CVS Caremark, Express Scripts, and OptumRx. The plaintiffs allege that manufacturers artificially inflated insulin list prices by more than 1,000% over two decades, while PBMs accepted large rebates in exchange for placing those high-list-price insulins on preferred formulary tiers. This arrangement allegedly generated billions in revenue for the supply chain while causing patients, self-funded employers, and government payers to pay far more than a competitive market would have produced.
What does the FTC’s settlement with Express Scripts actually require?
Under the February 2026 settlement, Express Scripts must restructure its formulary practices so that it no longer automatically gives preferred placement to high-list-price drugs over lower-cost alternatives. It must also delink its compensation from the amount of rebates it negotiates with drug manufacturers — removing the financial incentive that critics say drove it to favor expensive branded insulins. The FTC estimates these structural changes could save patients up to $7 billion in out-of-pocket costs over the next 10 years. The settlement does not by itself compensate patients for past harm, but it establishes a factual record that may support civil litigation.
Can individual diabetic patients file their own claims related to insulin pricing?
The current MDL 3080 is primarily populated by state attorneys general and self-funded employer health plans, but the legal theories underpinning those claims — including consumer protection law, RICO, and antitrust violations — can also support individual patient claims. Patients who paid inflated out-of-pocket prices for insulin, particularly those without comprehensive insurance coverage, should consult with a mass tort attorney about whether their circumstances support an individual claim or whether they may be eligible to participate in a future class action. Documentation of out-of-pocket expenses and medical records showing insulin dependence will be critical.
What is the significance of the June 1, 2026 order allowing amended complaints in MDL 3080?
When Judge Martinotti authorized self-funded payer plaintiffs to amend their complaints on June 1, 2026, he gave those plaintiffs an opportunity to incorporate new factual allegations and legal theories developed since the original complaints were filed. In complex mass tort litigation, amended complaints often integrate regulatory findings — such as those from the FTC — into the civil case, making dismissal more difficult for defendants. The June 1 order signals that this case is actively progressing and that plaintiffs are strengthening their legal positions with current evidence.
Does the dismissal of the PBMs’ 8th Circuit countersuit affect my potential claim?
Yes, indirectly but importantly. When all three PBMs filed a joint stipulation to end their countersuit against the FTC in July 2026 — resulting in the 8th Circuit’s dismissal — they eliminated a procedural roadblock that could have delayed or complicated the FTC’s administrative proceedings against them. With that obstacle removed, the FTC’s cases against CVS Caremark and OptumRx can proceed without the legal uncertainty that a live appellate challenge created. For civil plaintiffs in MDL 3080, a stronger and more accelerated FTC process means more regulatory findings that can be used as evidence in the civil litigation.
This content is for informational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction regarding any potential insulin pricing lawsuit claim.
Related reading: AI Medical Malpractice Liability: Who Is Responsible When Artificial Intelligence Harms A Patient? (2026 Guide)
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.